02179.HK
Jiangsu Recbio Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 5.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 38.4M | 12.4M | 27.0M | 30.4M | 5.3M |
| Cost of Revenue | 59.5M | 103.9M | 11.1M | 8.0M | — |
| Gross Profit | (21.1M) | (91.5M) | 15.9M | 22.3M | 5.3M |
| Operating Expenses | |||||
| R&D Expense | 874.1M | 481.4M | 476.1M | 487.8M | 716.4M |
| SG&A Expense | 152.1M | 13.9M | 111.7M | 152.2M | 164.0M |
| General & Admin Expense | 143.0M | — | 109.0M | 143.8M | 155.3M |
| Selling & Marketing Expense | 4.2M | — | 2.6M | 8.5M | 8.7M |
| Other Expenses | 65.7M | 2.0M | — | — | — |
| Total Operating Expenses | 1.1B | 497.4M | 587.8M | 640.1M | 880.4M |
| Cost and Expenses | 1.2B | 601.2M | 598.9M | 648.1M | 880.4M |
| Operating Income (EBIT) | (1.1B) | (588.9M) | (571.8M) | (617.7M) | (875.1M) |
| Non-Operating | |||||
| Interest Income | 11.9M | 2.7M | 2.5M | 32.0M | 24.0M |
| Interest Expense | 32.6M | 23.3M | — | — | 3.5M |
| Net Interest Income | (32.2M) | (20.6M) | 2.5M | 32.0M | 20.4M |
| Other Non-Op Income/Expense | (14.7M) | (3.6M) | 9.9M | 45.3M | 139.1M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (1.1B) | (592.5M) | (561.9M) | (572.4M) | (736.0M) |
| Income Tax Expense | 2.4M | 2.1M | — | — | (16.8M) |
| Bottom Line | |||||
| Net Income | (1.1B) | (594.6M) | (562.4M) | (572.0M) | (719.2M) |
| Earnings from Cont. Ops | (1.1B) | (594.6M) | (561.9M) | (572.4M) | (736.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.1B) | (594.6M) | (557.5M) | (572.0M) | (722.7M) |
| Per Share | |||||
| Basic EPS | (HK$2.13) | (HK$1.12) | (HK$1.16) | (HK$1.19) | (HK$1.52) |
| Diluted EPS | (HK$2.13) | (HK$1.12) | (HK$1.16) | (HK$1.19) | (HK$1.52) |
| Revenue Per Share | HK$0.06 | HK$0.02 | HK$0.06 | HK$0.06 | HK$0.01 |
| Shares | |||||
| Basic Shares Outstanding | 615.9M | 531.2M | 478.5M | 480.9M | 474.2M |
| Diluted Shares Outstanding | 615.9M | 531.2M | 478.5M | 480.9M | 474.2M |
| Profitability Metrics | |||||
| EBITDA | (933.6M) | (486.4M) | (524.0M) | (569.9M) | (847.7M) |
| D&A | 183.9M | 102.4M | 47.9M | 47.9M | 27.4M |
| EBIT | (1.1B) | (588.9M) | (571.8M) | (617.7M) | (875.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026